Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика НвfiledCriticalЯнссен Фармацевтика Нв
Priority claimed from PCT/EP2017/073001external-prioritypatent/WO2018050684A1/en
Publication of EA201990700A1publicationCriticalpatent/EA201990700A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Настоящее изобретение относится к фармацевтическим средствам, пригодным для терапии и/или профилактики у млекопитающего и, в частности, к конденсированным бициклическим соединениям, фармацевтической композиции, содержащей данные соединения, и к их применению в качестве ингибиторов белок-белковых взаимодействий менин-MLL, пригодных для лечения заболеваний, таких как рак, миелодиспластический синдром (MDS) и диабет.The present invention relates to pharmaceuticals suitable for the treatment and / or prophylaxis in a mammal, and in particular to fused bicyclic compounds, a pharmaceutical composition containing these compounds, and their use as menin-MLL protein-protein interactions inhibitors suitable for treating diseases such as cancer, myelodysplastic syndrome (MDS), and diabetes.
Compounds derived from substituted azaindolins, inhibitors of smac protein binding to apoptosis (iap) protein inhibitor and / or inhibitors of iap activated caspase protein binding; pharmaceutical composition that includes them; method to treat or improve cancer; and its use for the therapeutic and / or prophylactic treatment of cancer.